Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs.
作者信息
Dieppe Paul, Bartlett Christopher, Davey Peter, Doyal Lesley, Ebrahim Shah
机构信息
Medical Research Council Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol BS8 2PR.
出版信息
BMJ. 2004 Jul 3;329(7456):31-4. doi: 10.1136/bmj.329.7456.31.
Abstract
摘要
相似文献
1
Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs.
BMJ. 2004 Jul 3;329(7456):31-4. doi: 10.1136/bmj.329.7456.31.
2
Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy.
Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S14-8.
3
[Adverse effects of non-steroidal antirheumatic drugs with special reference to the gastrointestinal tract].
Z Rheumatol. 1987;46 Suppl 1:83-8.
4
Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
Am J Gastroenterol. 2003 May;98(5):1203-4; author reply 1204. doi: 10.1111/j.1572-0241.2003.07443.x.
5
Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Aliment Pharmacol Ther. 2004 May 15;19(10):1051-61. doi: 10.1111/j.1365-2036.2004.01935.x.
6
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi: 10.1517/14740338.2010.501331.
7
Non steroidal anti-inflammatory drugs.
Aust Fam Physician. 1987 Jun;16(6):799, 803, 805 passim.
8
Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
Gastroenterol Clin North Am. 2009 Jun;38(2):305-14. doi: 10.1016/j.gtc.2009.03.006.
9
Potential complications of nonsteroidal anti-inflammatory drug therapy.
J Am Podiatr Med Assoc. 1989 Dec;79(12):605-14. doi: 10.7547/87507315-79-12-605.
10
[Non steroidal anti-inflammatory drugs (NSAIDs) - balancing gastrointestinal complications and the cardiovascular risk].
Dtsch Med Wochenschr. 2009 Aug;134(33):1635-40; quiz 1641-4. doi: 10.1055/s-0029-1233993. Epub 2009 Jul 31.
引用本文的文献
1
Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses.
Syst Rev. 2023 Apr 15;12(1):67. doi: 10.1186/s13643-023-02234-0.
2
Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis.
BMC Nephrol. 2017 Aug 1;18(1):256. doi: 10.1186/s12882-017-0673-8.
3
Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease.
J Am Geriatr Soc. 2017 Nov;65(11):2354-2361. doi: 10.1111/jgs.14833. Epub 2017 Mar 17.
4
Evaluating ethnic differences in the prescription of NSAIDs for chronic kidney disease: a cross-sectional survey of patients in general practice.
Br J Gen Pract. 2014 Jul;64(624):e448-55. doi: 10.3399/bjgp14X680557.
5
Special considerations with the use of intravenous immunoglobulin in older persons.
Drugs Aging. 2011 Sep 1;28(9):729-36. doi: 10.2165/11592740-000000000-00000.
6
Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.
PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Epub 2011 May 3.
7
The role of tramadol in current treatment strategies for musculoskeletal pain.
Ther Clin Risk Manag. 2007 Oct;3(5):717-23.
8
European Medicines Agency policies for clinical trials leave women unprotected.
J Epidemiol Community Health. 2006 Nov;60(11):911-3. doi: 10.1136/jech.2006.048769.
9
Complicity theory: an explanation for the 'coxib problem'?
J R Soc Med. 2006 Jun;99(6):273-4. doi: 10.1177/014107680609900603.
10
Evaluating medical effectiveness for the california health benefits review program.
Health Serv Res. 2006 Jun;41(3 Pt 2):1007-26. doi: 10.1111/j.1475-6773.2006.00517.x.
本文引用的文献
1
The causes and effects of socio-demographic exclusions from clinical trials.
Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. doi: 10.3310/hta9380.
2
Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract.
Fundam Clin Pharmacol. 2003 Aug;17(4):393-403. doi: 10.1046/j.1472-8206.2003.00179.x.
3
Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain.
Arch Intern Med. 2002;162(22):2639-40; author reply 2640-2. doi: 10.1001/archinte.162.22.2639-a.
4
A comparison of the views of rheumatologists, general practitioners and patients on the treatment of osteoarthritis.
Rheumatology (Oxford). 2002 Oct;41(10):1208-10.
5
The impracticable nature of consent for research use of linked administrative health records.
Aust N Z J Public Health. 2001 Oct;25(5):421-2.
6
Risk of cardiovascular events associated with selective COX-2 inhibitors.
JAMA. 2001;286(8):954-9. doi: 10.1001/jama.286.8.954.
7
Age and gender bias in statin trials.
QJM. 2001 Mar;94(3):127-32. doi: 10.1093/qjmed/94.3.127.
8
Using patient-identifiable data for observational research and audit.
BMJ. 2000 Oct 28;321(7268):1031-2. doi: 10.1136/bmj.321.7268.1031.
9
Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint.
Ann Rheum Dis. 2000 Jun;59(6):414-8. doi: 10.1136/ard.59.6.414.
10
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.
Arch Intern Med. 2000 Mar 27;160(6):777-84. doi: 10.1001/archinte.160.6.777.
Zotero 插件